Uses of Zitad

Zitad drug is made in the form of tablets, with the main ingredient being Quetiapine. Drugs used to treat schizophrenia, bipolar disorder,...

Zitad medicine has the main ingredient Quetiapine (as Quetiapine fumarate). The drug has different strength forms such as Zitad 50, Zitad 200 equivalent to the content of Quetiapin in 1 tablet of 50mg, 200mg. Quetiapine is an atypical antipsychotic drug that acts on multiple neurotransmitter receptors. This active ingredient is more selective for serotonin (5HT2) receptors in the brain than dopamine D2 receptors, so it helps in clinical antipsychotic, less side effects on the extrapyramidal system.
Indications to use Zitad:
Treatment of schizophrenia; Treatment of manic episodes associated with bipolar disorder. Contraindications to the use of Zitad:
People with hypersensitivity or allergy to active ingredients or ingredients in the drug.

Usage: Orally.
Dosage:
Adults: Treatment of schizophrenia: Take Quetiapine 2 times a day, with or without meals. The total daily dose for the first 4 days of treatment was 50mg (day 1), 100mg (day 2), 200mg (day 3) and 300mg (day 4). From day 4 onwards, the dose should be adjusted to the usual effective dose of 300-450 mg/day. Depending on the clinical response and tolerability of the patient, the dose can be adjusted from 150 to 750 mg/day; Treatment of manic episodes associated with bipolar disorder: Take Quetiapine twice a day, with or without meals. Can be used as monotherapy or as adjunctive treatment for psychoactive drugs, the total daily dose for the first 4 days of drug use is 100mg (day 1), 200mg (day 2), 300mg (day 3) , 400mg (day 4). Dosage can be gradually adjusted up to 800mg/day on the 6th day of treatment with the requirement that each increase does not exceed 200mg/day. Dosage can be adjusted according to the clinical response and tolerability of the patient, in the range of 200-800mg/day. The usual effective dose is 400-800mg/day; Elderly: Quetiapine should be used with caution in the elderly, especially during the initiation period. Elderly patients should be started with Quetiapine 25 mg/day. The daily dose should be increased by 25-50mg to a therapeutically effective dose (usually lower than the effective dose in young adults); Children and Adolescents: The safety and effectiveness of quetiapine in children and adolescents have not been established. Patients with hepatic and renal impairment: Oral quetiapine clearance was reduced by approximately 25% in patients with hepatic or renal impairment. Since quetiapine is mainly metabolised in the liver, caution should be exercised when this drug is administered to patients with hepatic impairment. Ideally, patients with hepatic or renal impairment should be initiated with a dose of Quetiapine 25 mg/day. The daily dose should be increased by 25-50mg to a therapeutically effective dose. Overdose: In clinical trials, survivals have been reported with acute overdoses of up to 30 mg quetiapine. In the process of use, cases of Quetiapine overdose (not combined with other drugs) causing death or coma are very rare. Patients with pre-existing severe cardiovascular disease may be at increased risk of severe symptoms if the drug overdoses. Quetiapine overdose symptoms are mainly due to increased pharmacological effects of the drug such as hypotension, drowsiness, sedation, tachycardia. There is currently no specific antidote for quetiapine. In the case of severe toxicity, the possibility of multiple drug effects should be considered, and special care measures should be taken (including establishing and maintaining an airway, ensuring ventilation, providing oxygen, etc.). complete, monitoring and cardiovascular support). The patient should continue to be closely monitored and monitored until the patient is fully recovered.

When using Zitad, patients may experience some side effects such as:
Very common: Dizziness, dizziness and drowsiness; Common: Syncope, rhinitis, leukopenia, tachycardia, orthostatic hypotension, constipation, dyspepsia, dry mouth, mild asthenia, peripheral edema, weight gain, elevation of serum transaminases (AST, ALT), neutropenia, hyperglycemia to pathological levels; Uncommon: Eosinophilia, hypersensitivity, convulsions, tremor syndrome, increased gamma-GT4, increased total cholesterol (mainly LDL-C), increased serum triglycerides at any time; Rare: Neuroleptic malignant syndrome, erectile dysfunction, anaphylaxis,... When experiencing side effects of Zitad, patients should immediately notify their doctor for advice on how to manage , the most appropriate intervention.

Before and while using Zitad, patients should note:
Using Quetiapine can cause severe neutropenia (most cases occur in the first 2 months of treatment). Possible risk factors for neutropenia include: Pre-existing low white blood cell count, history of drug-induced neutropenia. Quetiapine should be discontinued in patients with neutrophil counts below 1.0 x 109/L. In addition, infection symptoms and neutrophil counts should be monitored in this group of patients until the neutrophil count exceeds 1.5 x 109/L; A few cases of using Quetiapine have increased blood glucose. Although the link between drug use and diabetes is unknown, people at risk for diabetes are advised to have regular health monitoring. At the same time, it is advisable to monitor for possible exacerbations in diabetics; Quetiapine should be used with caution in patients with cardiovascular disease, cerebrovascular disease, or other conditions that may cause hypotension. Quetiapine may cause orthostatic hypotension, especially in the early stages of dose adjustment, which is more common in elderly patients than in young adults; In clinical trials, quetiapine was not associated with an increase in QT interval prolongation. However, caution should be exercised when quetiapine is co-administered with drugs that prolong the QT interval, especially in elderly patients; In clinical trials, there was no difference in seizure frequency between quetiapine and placebo groups. However, caution should still be exercised when quetiapine is used in patients with a history of epilepsy; Quetiapine may cause tardive dyskinesia with prolonged treatment. In the presence of any symptoms of tardive dyskinesia, dose reduction or discontinuation of quetiapine should be considered; Neuroleptic malignant syndrome has been associated with the use of antipsychotics, including quetiapine. Clinical symptoms include extreme hyperthermia, muscle spasticity, altered mental status, autonomic instability, and increased creatine phosphokinase. In this case, it is best to discontinue quetiapine and initiate appropriate treatment; When quetiapine is abruptly stopped, patients may experience nausea, vomiting and insomnia (very rare). There is also a risk of recurrence of psychotic symptoms, and in some cases involuntary movement disorders (dystrophy, dyskinesia, dyskinesia). Therefore, the drug should be discontinued gradually; Quetiapine has not been approved for the treatment of dementia-related psychosis. In a meta-analysis of atypical antipsychotics, an increased risk of death was reported in elderly patients with dementia-related psychosis compared with placebo; Because Quetiapine can cause drowsiness, caution should be exercised when driving or operating machinery; The efficacy and safety of quetiapine for pregnant women have not been established. Therefore, quetiapine should be used during pregnancy only when the potential benefits outweigh the possible risks; The extent to which quetiapine is excreted in human milk is unknown. Therefore, the mother should stop breastfeeding while taking Quetiapine.

Some drug interactions of Zitad:
When Zitad is used simultaneously with alcohol, the patient has an increased risk of somnolence and orthostatic hypotension; CYP3A4 enzyme inducers such as carbamazepine and phenytoin may decrease quetiapine plasma concentrations; CYP3A4 enzyme inhibitors such as erythromycin, ketoconazole may increase plasma concentrations of quetiapine. When using Zitad, patients should strictly follow the doctor's instructions on the dose and method of taking the drug. This ensures the best treatment effect and avoids some of the risk of dangerous side effects.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.